Merck & Co. announced on Wednesday that it will acquire Terns Pharmaceuticals in a deal valued at up to $6.7 billion, as the drugmaker moves to strengthen its cancer treatment pipeline ahead of an expected patent expiry for its blockbuster therapy Keytruda.
25 Mar 2026-15:05
25 Mar 2026-15:05
